Cryptococcus neoformans var. grubii Franzot et al.
商品貨號(hào)
B168993
Deposited As
Cryptococcus neoformans (Sanfelice) Vuillemin
Strain Designations
7241/9.829 MCV 13 [NCCLS 98]
Application
susceptibility testing antifungal agents
Biomedical Research and Development Material
Biosafety Level
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Product Format
freeze-dried
Storage Conditions
Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section
Type Strain
no
Preceptrol®
no
Comments
Autonomous effect of combination of fluconazole and flucytosine
Medium
ATCC® Medium 28: Emmons' modification of Sabouraud's agar
ATCC® Medium 200: YM agar or YM broth
ATCC® Medium 323: Malt agar medium
Espinel-Ingroff A, et al. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 30: 3138-3145, 1992. PubMed: 1452697
Nguyen MH, et al. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob. Agents Chemother. 39: 1691-1695, 1995. PubMed: 7486902
Yamada Y, et al. Phylogenetic relationships among medically important yeasts based on sequences of mitochondrial large subunit ribosomal RNA gene. Mycoses 47: 24-28, 2004. PubMed: 14998395
Imai T, et al. Geographic grouping of Cryptococcus neoformans var. gattii by random amplified polymorphic DNA fingerprint patterns and ITS sequence divergence. Clin Lab 46: 345-354, 2000. PubMed: 10934581
